{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Continue+current+antiretroviral+regimen",
    "query": {
      "intervention": "Continue current antiretroviral regimen"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 24,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Continue+current+antiretroviral+regimen&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-29T19:23:59.366Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03639311",
      "title": "Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "CAB LA",
          "type": "DRUG"
        },
        {
          "name": "RPV LA",
          "type": "DRUG"
        },
        {
          "name": "RPV",
          "type": "DRUG"
        },
        {
          "name": "DTG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 97,
      "start_date": "2018-09-24",
      "completion_date": "2023-01-30",
      "has_results": true,
      "last_update_posted_date": "2024-06-11",
      "last_synced_at": "2026-09-29T19:23:59.366Z",
      "location_count": 25,
      "location_summary": "Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 20 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03639311"
    },
    {
      "nct_id": "NCT00145795",
      "title": "A Research Study to See if a Change in Therapy for HIV Infection Can Improve the Immune Response to Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Kaletra + Current Dual NRTI Backbone",
          "type": "DRUG"
        },
        {
          "name": "Current Regimen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 20,
      "start_date": "2004-04",
      "completion_date": "2009-12",
      "has_results": true,
      "last_update_posted_date": "2022-06-15",
      "last_synced_at": "2026-09-29T19:23:59.366Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00145795"
    },
    {
      "nct_id": "NCT06336434",
      "title": "CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HIV-1-infection",
        "Pregnancy",
        "Postpartum"
      ],
      "interventions": [
        {
          "name": "CAB LA 600mg",
          "type": "DRUG"
        },
        {
          "name": "RPV LA 900mg",
          "type": "DRUG"
        },
        {
          "name": "CAB LA 400mg",
          "type": "DRUG"
        },
        {
          "name": "RPV LA 600mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2025-05-01",
      "completion_date": "2028-01-30",
      "has_results": false,
      "last_update_posted_date": "2025-07-31",
      "last_synced_at": "2026-09-29T19:23:59.366Z",
      "location_count": 4,
      "location_summary": "La Jolla, California • Los Angeles, California • Baltimore, Maryland + 1 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06336434"
    },
    {
      "nct_id": "NCT01568892",
      "title": "Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Dolutegravir 50 mg twice daily",
          "type": "DRUG"
        },
        {
          "name": "Dolutegravir placebo twice daily",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2012-04-18",
      "completion_date": "2013-12-16",
      "has_results": true,
      "last_update_posted_date": "2018-07-02",
      "last_synced_at": "2026-09-29T19:23:59.366Z",
      "location_count": 25,
      "location_summary": "Little Rock, Arkansas • Bakersfield, California • Beverly Hills, California + 21 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01568892"
    },
    {
      "nct_id": "NCT00225017",
      "title": "Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infection",
        "Hyperlipidemia"
      ],
      "interventions": [
        {
          "name": "Atazanavir",
          "type": "DRUG"
        },
        {
          "name": "current antiretroviral regimen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2005-06",
      "completion_date": "2008-06",
      "has_results": true,
      "last_update_posted_date": "2012-08-02",
      "last_synced_at": "2026-09-29T19:23:59.366Z",
      "location_count": 5,
      "location_summary": "San Diego, California • Chicago, Illinois • Indianapolis, Indiana + 2 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00225017"
    },
    {
      "nct_id": "NCT01923311",
      "title": "Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Acquired Immune Deficiency Syndrome (AIDS)",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "EVG",
          "type": "DRUG"
        },
        {
          "name": "Background regimen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Weeks",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "4 Weeks to 17 Years"
      },
      "enrollment_count": 31,
      "start_date": "2013-08-26",
      "completion_date": "2017-11-03",
      "has_results": true,
      "last_update_posted_date": "2018-08-09",
      "last_synced_at": "2026-09-29T19:23:59.366Z",
      "location_count": 3,
      "location_summary": "Aurora, Colorado • Durham, North Carolina • Memphis, Tennessee",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01923311"
    },
    {
      "nct_id": "NCT07209267",
      "title": "Baricitinib Curative Repression of HIV-1",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infection",
        "HIV"
      ],
      "interventions": [
        {
          "name": "Antiretroviral Therapy (ART)",
          "type": "DRUG"
        },
        {
          "name": "Baricitinib (LY3009104) 2 mg",
          "type": "DRUG"
        },
        {
          "name": "Baricitinib (LY3009104) 4 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 35,
      "start_date": "2026-10",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-17",
      "last_synced_at": "2026-09-29T19:23:59.366Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07209267"
    },
    {
      "nct_id": "NCT00001131",
      "title": "Effectiveness of Interleukin-2 (IL-2) Plus Anti-HIV Therapy in HIV-Positive Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Aldesleukin",
          "type": "DRUG"
        },
        {
          "name": "HAART",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 42,
      "start_date": "2004-05",
      "completion_date": "2007-06",
      "has_results": false,
      "last_update_posted_date": "2015-05-15",
      "last_synced_at": "2026-09-29T19:23:59.366Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001131"
    },
    {
      "nct_id": "NCT00675844",
      "title": "An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Elvucitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 7,
      "start_date": "2008-05",
      "completion_date": "2010-03",
      "has_results": false,
      "last_update_posted_date": "2023-08-14",
      "last_synced_at": "2026-09-29T19:23:59.366Z",
      "location_count": 5,
      "location_summary": "Orlando, Florida • Pensacola, Florida • Newark, New Jersey + 2 more",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Pensacola",
          "state": "Florida"
        },
        {
          "city": "Newark",
          "state": "New Jersey"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00675844"
    },
    {
      "nct_id": "NCT04021290",
      "title": "Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults (SALSA)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "DTG/3TC FDC",
          "type": "DRUG"
        },
        {
          "name": "CAR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 493,
      "start_date": "2019-11-11",
      "completion_date": "2022-09-09",
      "has_results": true,
      "last_update_posted_date": "2023-10-19",
      "last_synced_at": "2026-09-29T19:23:59.366Z",
      "location_count": 16,
      "location_summary": "Los Angeles, California • Newport Beach, California • San Francisco, California + 12 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04021290"
    }
  ]
}